WuXi AppTec Co. Ltd. Takes Position in Lyell Immunopharma, Inc. (NASDAQ:LYEL)

WuXi AppTec Co. Ltd. purchased a new stake in shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 8,180,678 shares of the company’s stock, valued at approximately $15,871,000. Lyell Immunopharma accounts for approximately 41.2% of WuXi AppTec Co. Ltd.’s portfolio, making the stock its largest holding. WuXi AppTec Co. Ltd. owned approximately 3.25% of Lyell Immunopharma at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of LYEL. TD Asset Management Inc boosted its holdings in shares of Lyell Immunopharma by 112.1% in the third quarter. TD Asset Management Inc now owns 916,232 shares of the company’s stock valued at $1,347,000 after buying an additional 484,316 shares during the period. Rafferty Asset Management LLC raised its position in shares of Lyell Immunopharma by 30.6% in the third quarter. Rafferty Asset Management LLC now owns 424,886 shares of the company’s stock valued at $625,000 after buying an additional 99,597 shares in the last quarter. Barclays PLC lifted its position in shares of Lyell Immunopharma by 23.7% during the 3rd quarter. Barclays PLC now owns 245,243 shares of the company’s stock valued at $362,000 after acquiring an additional 46,975 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its holdings in Lyell Immunopharma by 1,052.7% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 225,506 shares of the company’s stock valued at $437,000 after buying an additional 205,942 shares during the period. Finally, Caxton Associates LP boosted its position in shares of Lyell Immunopharma by 346.9% during the 3rd quarter. Caxton Associates LP now owns 198,477 shares of the company’s stock worth $292,000 after acquiring an additional 154,064 shares in the last quarter. 66.05% of the stock is owned by institutional investors.

Lyell Immunopharma Price Performance

Shares of Lyell Immunopharma stock traded down $0.04 on Wednesday, hitting $2.50. 839,769 shares of the company’s stock traded hands, compared to its average volume of 966,912. Lyell Immunopharma, Inc. has a one year low of $1.32 and a one year high of $3.97. The company has a fifty day moving average of $2.33 and a two-hundred day moving average of $2.09. The company has a market capitalization of $637.35 million, a price-to-earnings ratio of -2.73 and a beta of -0.54.

Lyell Immunopharma (NASDAQ:LYEL) last issued its quarterly earnings data on Wednesday, February 28th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.01. Lyell Immunopharma had a negative net margin of 180,486.14% and a negative return on equity of 32.67%. The firm had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $4.96 million. Equities research analysts anticipate that Lyell Immunopharma, Inc. will post -0.84 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and set a $6.00 target price on shares of Lyell Immunopharma in a research note on Tuesday.

About Lyell Immunopharma

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.